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Abstract
Background: The adrenergic system and progesterone play major roles in the control of the uterine function. Our
aims were to clarify the changes in function and expression of the α2-adrenergic receptor (AR) subtypes after
progesterone pretreatment in late pregnancy.
Methods: Sprague Dawley rats from pregnancy day 15 were treated with progesterone for 7 days. The myometrial
expressions of the α2-AR subtypes were determined by RT-PCR and Western blot analysis. In vitro contractions were
stimulated with (−)-noradrenaline, and its effect was modified with the selective antagonists BRL 44408 (α2A), ARC
239 (α2B/C) and spiroxatrine (α2A). The accumulation of myometrial cAMP was also measured. The activated
G-protein level was investigated via GTPγS binding assays.
Results: Progesterone pretreatment decreased the contractile effect of (−)-noradrenaline through the α2-ARs. The
most significant reduction was found through the α2B-ARs. The mRNA of all of the α2-AR subtypes was increased.
Progesterone pretreatment increased the myometrial cAMP level in the presence of BRL 44408 (p < 0.001),
spiroxatrine (p < 0.001) or the spiroxatrine + BRL 44408 combination (p < 0.05). Progesterone pretreatment increased
the G-protein-activating effect of (−)-noradrenaline in the presence of the spiroxatrine + BRL 44408 combination.
Conclusions: The expression of the α2-AR subtypes is progesterone-sensitive. It decreases the contractile response
of (−)-noradrenaline through the α2B-AR subtype, blocks the function of α2A-AR subtype and alters the G protein
coupling of these receptors, promoting a Gs-dependent pathway. A combination of α2C-AR agonists and α2B-AR
antagonists with progesterone could be considered for the treatment or prevention of preterm birth.
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Background
The physiology of uterine quiescence and contractility is
very complex. Myometrial contraction is regulated by a
number of factors, such as female sexual hormones, the
adrenergic receptor (AR) system, ion channels and
transmitters. However, the exact cellular and molecular
events are still in question. Dysregulation of the myome-
trial contractility can lead to either preterm or slow-to-
progress labor. It is therefore crucial to understand the
mechanisms that regulate uterine contractility in order
to prevent or treat the pathological processes related to
the pregnant myometrium [1–4].
It is well known that the female sexual hormone pro-
gesterone is responsible for uterine quiescence [5, 6],
while estrogens have major role in myometrial contrac-
tions [1, 7]. The progesterone level normally declines at
term prior to the development of labor and it is there-
fore used to prevent threatening preterm birth [8, 9].
Progesterone and estrogen also play an important role in
the regulation of the adrenergic system [10]. Estrogen
decreases the expressions of the α2-AR subtypes and al-
ters the myometrial contracting effect of (−)-noradren-
aline by reduced coupling of the α2B-ARs to Gi protein
[11]. Progesterone enhances the synthesis of β2-ARs
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during gestation [12–14], and the number of activated
G-proteins [12, 15], and β2-AR agonists can therefore
theoretically be combined with progesterone in threaten-
ing premature labour [16]. The myometrial α1-AR is also
influenced by progesterone. It induces a change in the
Gq/Gi-activating property of the α1AD-AR in rats [17].
However, the effect of progesterone on the myometrial
α2-AR subtypes is still unknown. Since progesterone has
a major role in myometrial quiescence during human
parturition [18], it seems important to know its direct
influence on the α2-AR subtypes, which are also involved
in the mechanism of uterine contractions [19].
The α2-ARs have been divided into three groups [20,
21], the α2A, α2B and α2C subtypes. All of three receptor
subtypes bind to the pertussis toxin-sensitive Gi protein
[22] and decreases the activity of adenylyl cyclase (AC)
[23], but under certain circumstances α2-ARs can also
couple to Gs-proteins and increase adenylyl cyclase ac-
tivity [24]. All three receptor subtypes are involved in
various physiological functions, and especially in the car-
diovascular and central nervous systems [25]. Further-
more, all of them have been identified in both the
pregnant and the non-pregnant myometrium, and have
been shown to take part in both increased and decreased
myometrial contractions [26]. The α2B-ARs predominate
and mediate contraction at the end of gestation in rats,
decreasing the intracellular cAMP level, while the stimu-
lation of the myometrial α2A- and α2C-ARs increases the
cAMP level, and mediates only weak contractions [27].
Since no data are available on the effects of progester-
one on the myometrial functions of the different α2-AR
subtypes, we set out to clarify the changes in expression
and function of the α2A-, α2B- and α2C-AR subtypes after
progesterone pretreatment on the last day of pregnancy
in rats.
Methods
The animal experimentation was carried out with the
approval of the Hungarian Ethical Committee for
Animal Research (permission number: IV/198/2013).
The animals were treated in accordance with the EU
Directive 2010/63/EU for animal experiments and the
Hungarian Act for the Protection of Animals in Research
(XXVIII. tv. 32.§).
Housing and handling of the animals
Sprague–Dawley rats were obtained from the INNOVO
Ltd. (Gödöllő, Hungary) and were housed under con-
trolled temperature (20–23 °C), in humidity (40–60%)
and light (12 h light/dark regime)-regulated rooms. The
animals were kept on a standard rodent pellet diet
(INNOVO Ltd., Isaszeg, Hungary), with tap water avail-
able ad libitum.
Mating of the animals
Mature female (180–200 g) and male (240–260 g)
Sprague–Dawley rats were mated in a special mating
cage in the early morning hours. A time-controlled
metal door separated the rooms for the male and female
animals. The separating door was opened before dawn
(4 a.m.) Within 4–5 h after the possibility of mating,
intercourse was confirmed by the presence of a copula-
tion plug or vaginal smears. In positive cases, the female
rats were separated and this was regarded as the first
day of pregnancy.
In vivo sexual hormone treatments of the rats
The progesterone (Sigma-Aldrich, Budapest, Hungary)
pretreatment of the pregnant animals was started on day
15 of pregnancy. Progesterone was dissolved in olive oil
and injected subcutaneously every day up to day 21 in a
dose of 0.5 mg/0.1 ml [28].
On day 22, the uterine samples were collected, and
contractility and molecular pharmacological studies were
carried out.
RT-PCR studies
Tissue isolation: Rats (250–350 g) were sacrificed by
CO2 asphyxiation. Fetuses were sacrificed by immediate
cervical dislocation. The uterine tissues from pregnant
animals (tissue between two implantation sites) were
rapidly removed and placed in RNAlater Solution
(Sigma-Aldrich, Budapest, Hungary). The tissues were
frozen in liquid nitrogen and then stored at −70 °C until
the extraction of total RNA.
Total RNA preparation from tissue: Total cellular
RNA was isolated by extraction with guanidinium
thiocyanate-acid-phenol-chloroform according to the
procedure of Chomczynski and Sacchi [29]. After pre-
cipitation with isopropanol, the RNA was washed with
75% ethanol and then re-suspended in diethyl
pyrocarbonate-treated water. RNA purity was controlled
at an optical density of 260/280 nm with BioSpec Nano
(Shimadzu, Japan); all samples exhibited an absorbance
ratio in the range 1.6–2.0. RNA quality and integrity
were assessed by agarose gel electrophoresis.
Reverse transcription and amplification of the PCR
products was performed by using the TaqMan RNA-to-
CTTM 1-Step Kit (Life Technologies, Budapest, Hungary)
and the ABI StepOne Real-Time cycler. RT-PCR amplifi-
cations were performed as follows: 48 °C for 15 min and
95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s
and 60 °C for 1 min. The generation of specific PCR prod-
ucts was confirmed by melting curve analysis. Table 1
contains the assay IDs for the used primers. The amplifi-
cation of β-actin served as an internal control. All samples
were run in triplicates. The fluorescence intensities of the
probes were plotted against PCR cycle numbers. The
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amplification cycle displaying the first significant increase
in the fluorescence signal was defined as the threshold
cycle (CT).
Western blot analysis
Twenty μg of protein per well was subjected to electro-
phoresis on 4–12% NuPAGE Bis-Tris Gel in XCell Sure-
Lock Mini-Cell Units (Life Technologies, Budapest,
Hungary). Proteins were transferred from gels to nitro-
cellulose membranes, using the iBlot Gel Transfer Sys-
tem (Life Technologies, Hungary). The antibody binding
was detected with the WesternBreeze Chromogenic
Western blot immundetection kit (Life Technologies,
Budapest, Hungary). The blots were incubated on a
shaker with α2A-AR, α2B-AR, α2C-AR and β-actin poly-
clonal antibody (Santa Cruz Biotechnology, California,
1:200) in the blocking buffer. Images were captured with
the EDAS290 imaging system (Csertex Ltd., Hungary),
and the optical density of each immunoreactive band
was determined with Kodak 1D Images analysis soft-
ware. Optical densities were calculated as arbitrary units
after local area background subtraction.
Isolated organ studies
Uteri were removed from the 22-day-pregnant rats
(250–350 g). 5 mm-long muscle rings were sliced from
both horns of the uterus and mounted vertically in an
organ bath containing 10 ml de Jongh solution (compos-
ition: 137 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM
MgCl2, 12 mM NaHCO3, 4 mM NaH2PO4, 6 mM glu-
cose, pH = 7.4). The temperature of the organ bath was
maintained at 37 °C, and carbogen (95% O2 + 5% CO2)
was perfused through the bath. After mounting, the
rings were allowed to equilibrate for approximately 60
min before experiments were started, with a buffer
change every 15 min. The initial tension of the prepar-
ation was set to about 1.5 g and the tension dropped to
about 0.5 g by the end of the equilibration period. The
tension of the myometrial rings was measured with a
gauge transducer (SG-02; Experimetria Ltd., Budapest,
Hungary) and recorded with a SPEL Advanced ISOSYS
Data Acquisition System (Experimetria Ltd., Budapest,
Hungary). In the following step contractions were elic-
ited with (−)-noradrenaline (10−8 to 10-4.5 M) and
cumulative concentration–response curves were con-
structed in each experiment in the presence of doxazosin
(10−7 M) and propranolol (10−5 M) in order to avoid α1-
adrenergic and β-adrenergic actions. Selective α2-AR
subtype antagonists (each 10−7 M), propranolol and doxa-
zosin were left to incubate for 20 min before the adminis-
tration of contracting agents. Following the addition of
each concentration of (−)-noradrenaline, recording was
performed for 300 s. Concentration–response curves were
fitted and areas under curves (AUC) were evaluated and
analysed statistically with the Prism 4.0 (Graphpad Soft-
ware Inc. San Diego, CA, USA) computer program. From
the AUC values, Emax and EC50 values were calculated.
Statistical evaluations were carried out with the ANOVA
Dunnett test or the two-tailed unpaired t-test.
Measurement of uterine cAMP accumulation
Uterine cAMP accumulation was measured with a
commercial cAMP Enzyme Immunoassay Kit (Cayman
Chemical, USA). Uterine tissue samples (control and
17β-estradiol-treated) from 22-day-pregnant rats were
incubated in an organ bath (10 ml) containing de Jongh
solution (37 °C, perfused with carbogen). Isobutyl-
methylxanthine (10−3 M), doxazosin (10−7 M), propranolol
(10−5 M) and the investigated subtype-selective α2-AR an-
tagonists (each 10−7 M) were incubated with the tissues
for 20 min, and (−)-noradrenaline (3 × 10−6 M) were
added to the bath for 10 min. At the end of the (−)-nor-
adrenaline incubation period, forskolin (10−5 M) was
added for another 10 min. After stimulation, the samples
were immediately frozen in liquid nitrogen and stored
until the extraction of cAMP [30]. Frozen tissue samples
were then ground, weighed, homogenized in 10 volumes
of ice-cold 5% trichloroacetic acid and centrifuged at
1000g for 10 min. The supernatants were extracted with 3
volumes of water-saturated diethyl ether. After drying, the
extracts were stored at −70 °C until the cAMP assay. Uter-
ine cAMP accumulation was measured with a commercial
competitive cAMP EIA Kit; tissue cAMP levels were
expressed in pmol/mg tissue.
[35S]GTPγS binding assay
Uteri were removed and homogenized in 20 volumes
(w/v) of ice-cold buffer (10 mM Tris–HCl, 1 mM EDTA,
Table 1 Parameters of the applied primers and PCR reactions. The real-time reverse transcription polymerase chain reactions were
used to determine the changes in the mRNA expression. In our studies the parameters of inventoried TaqMan assays were defined
by Life Technologies (ThermoFisher Scientific, Hungary)
TaqMan assays Assay ID (Life Technologies, Hungary) Accession number Assay location Amplicon length Annealing temp. (°C) Reaction volume (μl)
α2A-AR Rn00562488_s1 NM_012739.3 1350 72 60 20
α2B-AR Rn00593312_s1 NM_138505.2 1451 63 60 20
α2C-AR Rn00593341_s1 NM_138506.1 653 111 60 20
β-actin Rn00667869_m1 NM_031144.3 881 91 60 20
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0.6 mM MgCl2, and 0.25 M sucrose, pH 7.4) with an
Ultra Turret T25 (Janke & Kunkel, Staufen, Germany)
homogenizer, and the suspension was then filtered on
four layers of gauze and centrifuged (40,000g, 4 °C, 20
min). After centrifugation, the pellet was resuspended in
a 5-fold volume of buffer. The protein contents of the
samples were diluted to 10 mg protein/sample. Mem-
brane fractions was incubated in a final volume of 1 ml
at 30 °C for 60 min in Tris-EGTA buffer (pH 7.4) com-
posed of 50 mM Tris–HCl, 1 mM EGTA, 3 mM MgCl2,
100 mM NaCl, containing 20 MBq/0.05 cm3 [35S]GTPγS
(0.05 nM) (Sigma Aldrich, Budapest, Hungary), to-
gether with increasing concentrations (10−9–10−5 M)
of (−)-noradrenaline. BRL 44408, ARC 239 and spir-
oxatrine were used in a fixed concentration of 0.1 μM.
For the blocking of α1- and β-ARs, doxazosin and pro-
pranolol were used in a fixed concentration of 10 μM.
Total binding was measured in the absence of the li-
gands, non-specific binding was determined in the
presence of 10 μM unlabeled GTPγS and subtracted
from total binding. The difference represents basal activ-
ity. Bound and free [35S]GTPγS were separated by vacuum
filtration through Whatman GF/B filters with Brandel
M24R Cell harvester. Filters were washed three times with
5 ml ice-cold buffer (pH 7.4), and the radioactivity of the
dried filters was detected in UltimaGold™ MV scintillation
cocktail with Packard Tricarb 2300TR liquid scintillation
counter [31]. The [35S]GTPγS binding experiments were
performed in triplicate and repeated at least three times.
Gi protein was inhibited with pertussis toxin (Sigma
Aldrich, Budapest, Hungary) in a concentration of 500 ng/ml
after the addition of protein and GDP to the Tris-EGTA
buffer 30 min before [35S]GTPγS.
Results
RT-PCR and Western blot studies
The mRNA expression of each α2-AR subtype (Fig. 1a-c)
was significantly increased after progesterone pretreat-
ment as compared with the non-treated uteri (p < 0.05).
The results of Western blot analysis at the level of pro-
tein expression revealed a significant increase in each
α2-AR subtype, which correlated with the PCR results
(Fig. 2a-f ).
Isolated organ studies
In the 22-day-pregnant myometrium, (−)-noradrenaline
in the concentration range of 10−8 to 10-4.5 M increased
the myometrial contractions (Emax = 274.1 ± 47.1) (Fig. 3a).
After progesterone pretreatment, the myometrial con-
tracting effect of (−)-noradrenaline was decreased (Emax =
94.0 ± 14.4; p < 0.01) (Fig. 3b). The EC50 and Emax values
of the curves are listed in Table 2a.
In the presence of the α2A-AR antagonist BRL 44408, pro-
gesterone pretreatment decreased the (−)-noradrenaline-
evoked contractions as compared with the progesterone-
treated control (p < 0.05) (Fig. 3b). BRL 44408 enhanced
the (−)-noradrenaline-induced contractions, this be-
ing markedly reduced by progesterone pretreatment
(p < 0.001) (Fig. 3a, b; Table 2b).
In the presence of the α2B/C-AR antagonist ARC 239,
progesterone pretreatment did not modify the myome-
trial contracting effect of (−)-noradrenaline relative to
the progesterone-treated control. The concentration-
response curve was very flat, the difference between the
Fig. 1 Changes in the myometrial mRNA and protein expression of
the α2A- (a), α2B- (b) and α2C-adrenergic receptors (c) after progesterone
pretreatment. The statistical analyses were carried out with the
two-tailed unpaired t-test. *p < 0.05 ; ** p < 0.01
Hajagos-Tóth et al. Reproductive Biology and Endocrinology  (2016) 14:33 Page 4 of 9
minimum and the maximum effect was less then 20%
(Fig. 3b). ARC 239 reduced the (−)-noradrenaline-induced
contractions, which were decreased further by progester-
one pretreatment (p < 0.05) (Fig. 3a, b; Table 2c).
Progesterone pretreatment decreased the maximum
contracting effect of (−)-noradrenaline in the presence
of spiroxatrine as compared with the progesterone-
treated control (p < 0.05) (Fig. 3b). Spiroxatrine enhanced
the (−)-noradrenaline-induced contractions, which were
enormously reduced by progesterone pretreatment
(p < 0.001) (Fig. 3a, b; Table 2d).
In the presence of the combination of spiroxatrine + BRL
44408, progesterone pretreatment did not modify the max-
imum myometrial contracting effect of (−)-noradrenaline
in comparison with the progesterone-treated control
(Fig. 3b). The combination of the two compounds in-
creased the (−)-noradrenaline-induced contractions, which
were reduced by progesterone pretreatment (p < 0.001)
(Fig. 3a, b; Table 2e).
cAMP studies
Progesterone pretreatment increased the myometrial
cAMP level (p < 0.05) (Fig. 4) produced in the presence
of (−)-noradrenaline. The myometrial cAMP level was
also increased in the presence of BRL 44408 (p < 0.001),
spiroxatrine (p < 0.001) and the spiroxatrine + BRL
44408 combination (p < 0.05). However, ARC 239 did
not modify the amount of myometrial cAMP level after
progesterone pretreatment. In addition, BRL 44408
(p < 0.05) and spiroxatrine (p < 0.01) increased the myo-
metrial cAMP level compared to the progesterone-treated
control.
[35S]GTPγS binding assay studies
In the presence of BRL 44408, (−)-noradrenaline
increased the [35S]GTPγS binding, which was slightly
decreased after progesterone pretreatment (p < 0.01). In
the presence of pertussis toxin, the [35S]GTPγS binding-
stimulating effect of (−)-noradrenaline ceased, and it
Fig. 2 Changes in the α2-adrenergic receptor levels in the 22-day pregnant rat myometrium after progesterone pretreatment. The α2-adrenergic
receptor and β-actin Western blot products for α2A- (b), α2B- (d) and α2C-adrenergic receptors (f). The 70, 62 and 60 kDa proteins relate to the
α2AR-, α2B- and α2C- adrenergic receptors and β-actin, respectively. The antibody binding was expressed as optical density (OD) data (a) for α2A-,
(c) for α2B-and (e) for α2C-adrenergic receptors. The y axis shows the ratio of α2-adrenergic receptors/β-actin protein optical densities. The statistical
analyses were carried out with the two-tailed unpaired t-test. * p < 0.05; ** p < 0.01
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was decreased further after progesterone pretreatment
(p < 0.01) (Fig. 5a).
In the presence of ARC 239, (−)-noradrenaline moder-
ately increased the [35S]GTPγS binding and it was more
elevated after progesterone pretreatment (p < 0.01). In
the presence of pertussis toxin, the [35S]GTPγS binding-
stimulating effect of (−)-noradrenaline ceased, which
was not modified even by progesterone pretreatment
(Fig. 5b).
In the presence of spiroxatrine, (−)-noradrenaline
slightly increased the [35S]GTPγS binding and it was
more elevated (p < 0.001) after progesterone pretreat-
ment. In the presence of pertussis toxin, however,
Fig. 3 Effects of the subtype-selective α2A-adrenergic receptor
antagonist BRL 44408, the α2B/C-adrenergic receptor antagonist ARC
239 and the α2C-adrenergic receptor antagonist spiroxatrine on the
(−)-noradrenaline-evoked contractions in the 22-day-pregnant rat
myometrium (a) and after progesterone pretreatment (b). The
studies were carried out in the presence of the β-adrenergic receptor
antagonist propranolol (10−5 M) and the α1-adrenergic receptor
antagonist doxazosin (10−7 M) in each case. The change in
contraction was calculated via the area under the curve and
expressed in % ± S.E.M. The statistical analyses were carried out
with the ANOVA Dunnett test. *p < 0.05; **p < 0.01; ***p < 0.001
Table 2 Changes in the uterus-contracting effect of
(−)-noradrenaline (EC50 and Emax values) in the absence of
α2-antagonists (a), or in the presence of an α2A-antagonist (b),
an α2B/C-antagonist (c), an α2C-antagonist (d) or an α2A- and
an α2C-antagonists (e) in the 22-day-pregnant rat without and
after progesterone pretreatment
EC50 (M ± S.E.M.) Emax (% ± S.E.M)
(a) CONTROL
Non-treated 2.6×10−6 ± 1.2×10−6 274.1 ± 47.1
Progesterone-pretreated 1.7×10−6 ± 7.8×10−7 ns 94.0 ± 14.4 **
(b) BRL 44408
Non-treated 1.8×10−6 ± 6.4×10−6 364.3 ± 70.8
Progesterone-pretreated 1.2×10−5 ± 4.8 ×10−6 ns 57.4 ± 12.9 ***
(c) ARC 239
Non-treated 1.2×10−6 ± 1.1×10−6 147.1 ± 79.4
Progesterone-pretreated 5.3×10−6 ± 1.5×10−6 ns 83.7 ± 22.1*
(d) SPIROXATRINE
Non-treated 1.6×10−6 ± 5.4×10−6 382.4 ± 93.5
Progesterone-pretreated 5.9×10−6 ± 1.4×10−6 ns 41.0 ± 15.2 ***
(e) BRL 44408 + SPIROXATRINE
Non-treated 2.9×10−6 ± 8.4×10−7 444.6 ± 51.3
Progesterone-pretreated 2.8×10−6 ± 2.7 ×10−5 ns 102.9 ± 32.62 ***
EC50: the concentration of (−)-noradrenaline alone or in the presence of an
α2-AR antagonist which elicits half of the maximum contracting effect of
(−)-noradrenaline. Emax: the maximum contracting effect of (−)-noradrenaline
alone or in the presence of an α2-AR antagonist. Significance levels were
calculated in comparison with non-treated values. ns: not significant;
*: p < 0.05; **: p < 0.01; ***: p < 0.001
Fig. 4 Effects of the subtype-selective α2A-adrenergic receptor
antagonist BRL 44408, the α2B/C-adrenergic receptor antagonist ARC
239 and the α2C-adrenergic receptor antagonist spiroxatrine on the
myometrial cAMP level (pmol/mg tissue ± S.D.) in the presence of
isobutylmethylxanthine (10−3 M) and forskolin (10−5 M) (control) in
the 22-day-pregnant rat (n = 6) after progesterone pretreatment. The
statistical analyses were carried out with ANOVA followed by Dunnett’s
Multiple Comparison Test. *p < 0.05; **p < 0.01; ***p < 0.001
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(−)-noradrenaline elicited a decline in the [35S]GTPγS
binding, to below the basal level from a concentration of
1 × 10−9 M. In the presence of pertussis toxin, progesterone
pretreatment blocked the [35S]GTPγS binding-inhibitory
effect of (−)-noradrenaline (Fig. 5c).
In the presence of the spiroxatrine + BRL 44408 com-
bination, (−)-noradrenaline inhibited the [35S]GTPγS
binding, but it was significantly increased after proges-
terone pretreatment (p < 0.001). In the presence of per-
tussis toxin, the spiroxatrine + BRL 44408 combination
caused a dose-dependent inhibition in the [35S]GTPγS
binding of (−)-noradrenaline, but the inhibition was
reduced after progesterone pretreatment (Fig. 5d).
Discussion
Since progesterone and the adrenergic system play
major roles in the myometrial function during gesta-
tion, the main focus of our study was to clarify the
effects of progesterone on the α2-AR subtypes in the
late-pregnant uterine function in vitro. The α2-AR-se-
lective action of (−)-noradrenaline was provided by the
application of the α1-blocker doxazosin and the β-AR
blocker propanolol. The applications of subtype-selective
antagonists gave us the possibility to investigate the
subtype-specific α2-AR responses to (−)-noradrenaline
and to detect the modification induced by progesterone
pretreatment. In an earlier study, we determined the
subtype-selective α2-AR action of (−)-noradrenaline,
and our present work therefore focused mainly on
the influence of progesterone as a modifier of the α2-AR
response [27].
Progesterone pretreatment increased the mRNA and
protein expression of the myometrial α2-AR subtypes,
but decreased the (−)-noradrenaline-evoked myometrial
contraction through the α2-ARs, which was similar to
our earlier findings with the α1-ARs [17].
Fig. 5 Changes induced by various concentrations of noradrenaline in [35S]GTPγS binding in the presence of the subtype-selective α2A-adrenergic
receptor antagonist BRL 44408 (a), the α2B/C-adrenergic receptor antagonist ARC 239 (b), the α2C-adrenergic receptor antagonist spiroxatrine (c)
and the spiroxatrine + BRL 44408 combination (d) following pretreatment with progesterone. In all cases, the β-adrenergic receptors and the
α1-adrenergic receptors were inhibited by propranolol and doxazosin. Basal refers to the level of [
35S]GTPγS binding without substance. The
statistical analyses were carried out with the ANOVA Dunnett test. **p < 0.01; ***p < 0.001
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In the isolated organ bath studies, progesterone pre-
treatment ceased the (−)-noradrenaline-evoked myome-
trial contraction through the α2-ARs, although it
practically ceased the myometrial contracting effect of
the (−)-noradrenaline through the α2A-ARs. Addition-
ally, it abolished the myometrial contraction-increasing
effect through the α2B-ARs, and reversed the myometrial
contracting effect in the presence of BRL 44408 and in
the presence of spiroxatrine. Since there are no available
α2A/B-AR blockers to produce only α2C-AR stimulation,
we can only presume that progesterone maintained the
myometrial relaxing effect through the increased num-
ber and function of α2C-ARs.
To find an explanation of the weaker myometrial con-
tractions via the α2B-AR subtype after progesterone pre-
treatment, we measured the myometrial cAMP level,
since the changes in the cAMP level are involved in the
myometrial effect of the α2-ARs. Progesterone pretreat-
ment increased the myometrial cAMP level, which add-
itionally proves the decreased myometrial contracting
effect of (−)-noradrenaline through the α2-ARs. It did
not alter the cAMP level through the α2A-ARs, which is
in harmony with the result of the isolated organ bath
studies that (−)-noradrenaline did not influence the
myometrial contractions via these receptors after proges-
terone pretreatment. However, it increased the myome-
trial cAMP level through the α2B-ARs, which can
explain the weaker myometrium-contracting effect of
(−)-noradrenaline in the presence of BRL 44408 (stimu-
lation via α2B- and α2C-ARs), spiroxatrine (stimulation
via α2A- and α2B-ARs) and the spiroxatrine + BRL 44408
combination (stimulation via α2B-AR).
The literature indicates that the Gi/Gs-activating prop-
erty of α2-AR in rats changes during gestation, resulting
in differences in the regulation of myometrial adenylyl
cyclase activity at mid-pregnancy versus term [32].
Moreover, progesterone induces a change in the Gq/Gi-
activating property of α1AD-AR in rats [17]. We there-
fore measured whether progesterone can modify the
myometrial [35S]GTPγS binding of the α2-AR subtypes
in the presence of the Gi protein blocker pertussis toxin
at the end of pregnancy. Progesterone did not modify
the [35S]GTPγS binding of the α2A-ARs. However, via the
α2A- and α2B-ARs (with spiroxatrine), progesterone re-
versed the effect of (−)-noradrenaline on the [35S]GTPγS
binding in the presence of pertussis toxin and also in-
creased the [35S]GTPγS binding-stimulating effect of
(−)-noradrenaline. These findings indicate that progester-
one modifies the coupling of α2B-ARs, but not the G pro-
tein binding of the α2A-ARs. To confirm this hypothesis,
we measured the myometrial [35S]GTPγS binding of the
α2B-AR subtype in the presence of the spiroxatrine + BRL
44408 combination. Progesterone reversed the effect of
(−)-noradrenaline on [35S]GTPγS binding in the presence
of pertussis toxin and also reversed the [35S]GTPγS
binding-stimulating effect of (−)-noradrenaline. This result
suggests that, in the presence of predominance of proges-
terone, the α2B-ARs are coupled, at least partially, to Gs
protein, which leads to the activation of adenylyl cyclase
and decreases the (−)-noradrenaline-induced myometrial
contraction via these receptors.
Conclusions
We conclude that progesterone increases the expression
of each α2-AR subtype, and reduces the (−)-noradrenaline-
induced myometrial contractions via the totality of these
receptors. Progesterone blocks the G-protein coupling and
cAMP production via the α2A-ARs. In the case of the α2C-
ARs, we presume that progesterone treatment mainly in-
duces the activation of the βγ subunit of the Gi protein,
eliciting an increase in the smooth muscle cAMP level
[19]. In the case of the α2B-ARs, Gs coupling is a determin-
ing factor in the function of the receptors after progester-
one treatment, which leads to an increased cAMP level
and decreased myometrial contraction.
Since the myometrial sensitivity to progesterone de-
creases at term, we assume that these changes can lead
to the increased myometrial contraction near term via
the α2-ARs. We presume that the effects of α2C-AR ago-
nists and α2B-AR antagonists in combination with pro-
gesterone may open up new targets for drugs against
premature birth.
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